Related Experiment Video
Updated: Jun 19, 2026
17:16
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
Published on: December 9, 2010
Biomarkers in Clinical Trials--SMi Conference. 23-24 September 2009, London, UK
1Thomson Reuters, Hatton Garden, London, EC1N 8JS, UK. glenda.walker@thomsonreuters.com
Idrugs : the Investigational Drugs Journal
|October 22, 2009
Summary
This conference report covers new developments in biomarkers for clinical trials. It highlights biomarker definitions, applications in drug development, and treatment outcomes, featuring selumetinib.
Area of Science:
- Biomarkers and Translational Science
- Clinical Trial Design and Drug Development
Background:
- The Biomarkers in Clinical Trials conference convened experts to discuss advancements in biomarker research.
- Key areas included the evolving definition and application of biomarkers.
Purpose of the Study:
- To summarize critical discussions from the conference on biomarker utility.
- To highlight the role of biomarkers in informing drug development decisions and enhancing patient treatment.
- To present a case study on the investigational drug selumetinib.
Main Methods:
- Review of selected presentations from the Biomarkers in Clinical Trials conference.
- Focus on discussions regarding biomarker definition, drug development support, and treatment outcome improvement.
- Inclusion of a case study involving selumetinib.
Main Results:
- The conference underscored the importance of clear biomarker definitions.
- Biomarkers were presented as crucial tools for supporting decision-making in drug development.
- Evidence suggests biomarkers can significantly improve patient treatment outcomes.
Conclusions:
- Biomarker development and application are rapidly advancing.
- Strategic use of biomarkers is essential for efficient drug development and personalized medicine.
- The Biomarkers Consortium aims to further standardize and promote biomarker utilization.
